मधुबनी, अप्रैल 16 -- भरत प्रसाद लौकही । लौकही थाना क्षेत्र में धवही और बलुआ के बीच एनएच-227 पर बुधवार देर रात दो बाइक की आमने-सामने टक्कर में दो युवकों की मौके पर मौत हो गई। हादसे में तीन अन्य युवक गं... Read More
India, April 16 -- Independent Bank Corp. (INDB) released earnings for its first quarter that Increases, from last year The company's earnings came in at $79.92 million, or $1.63 per share. This comp... Read More
Singapore, April 16 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combi... Read More
Singapore, April 16 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the p... Read More
Singapore, April 16 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-98650... Read More
Singapore, April 16 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemother... Read More
Singapore, April 16 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safe... Read More
Singapore, April 16 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) ... Read More
Singapore, April 16 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig ... Read More
Singapore, April 16 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig ... Read More